7th Complement Drug Development

Memo

Returning for its 7th year, the Complement-Based Drug Development Summit evaluates the entirety of the complement landscape, from scientific understanding to strategic, commercial intelligence. This summit returns in a timely fashion to delve into the expanding therapeutic opportunities: from understanding the degree of complement inhibition needed, to mitigating toxicity effects with targeted approaches, hear how clinical scientists are optimizing clinical development by uncovering predictive biomarkers better informing patient populations, interpreting results, and strategizing regulatory approval across ophthalmology, neurology, haematology, and nephrology. New for 2023, a full pre-conference workshop composed of 4 deep diving discursive sessions split into a preclinical and clinical stream, both dedicated to overcoming the bottlenecks, and progressing development no matter what stage your pipeline is. Network with 150+ of your industry colleagues from around the globe, join the largest community of complement-based drug development experts to build meaningful connections and gather insights beyond the literature. URLs:Tickets: https://go.evvnt.com/1776132-2?pid=5569 Brochure: https://go.evvnt.com/1776132-3?pid=5569  Date and Time: On Mon, 11 Sep 2023 09:00 - Wed, 13 Sep 2023 18:00 Venue details: Hilton Boston Logan Airport, One Hotel Drive, Boston, Massachusetts, 02128, United States Prices:Drug Developer - Conference + Pre-Clinical Workshop: USD 4597.00,Drug Developer - Conference + Clinical Workshop: USD 4597.00,Drug Developer - Conference Only: USD 3199.00,Solution Provider - Conference + Pre-Clinical Workshop: USD 5497.00,Solution Provider - Conference + Clinical Workshop: USD 5497.00,Solution Provider - Conference Only: USD 3899.00,Academic - Conference + Pre-Clinical Workshop: USD 3997.00,Academic - Conference + Clinical Workshop: USD 3997.00,Academic - Conference Only: USD 2799.00 Speakers: Abraham Scaria, Chief Scientific Officer, AGTC, Alberto Cruz-Martin, Assistant Professor, Boston University, Anna Borodovsky, Vice President and Director - Research, Alnylam Pharmaceuticals, Aude Gobert, Director of Global Regulatory Affairs, UCB, Dhaval Desai, Senior Vice President and Chief Development Officer, IVERIC bio, Dmitry Samarsky, Chief Technology Officer, Sirnaomics, Donna Flesher, VP Biomarker and Bioanalytical Sciences, HIBio, Erik Toonen, Senior Scientist, Research, Hycult Biotech, Guillemette Masse Ranson, Associate Scientific Director, Immunology Research, Moderna, Irene Von Hennings, Vice President, Medical Affairs, Amgen, Kapil Bharti, Senior Investigator, National Institute of Health Science, Lori Taylor, Senior Vice President, Portfolio Strategy and Operations, Annexon Biosciences, Martin Kolev, Associate Director Complement Science, Apellis Pharmaceuticals, Martin Schmidt, Chief Scientific Officer, Kypha, Inc., Matthew Albert, CTO, HIBio, Michael Schwenkert, Chief Product and Technology Officer, Svar Life Science AB, Michael Storek, Head of Complement and Cluster, Sanofi, Michelle Elvington, Scientific Director- Complement and Clinical Development, Kypha, Inc., Nader Najafian, Executive Director - Clinical Development Sciences, Alexion Pharmaceuticals, Niels Riedemann, CEO, Inflarx N. V., Pascal Deschatelets, Co-Founder and Chief Scientific Officer Operations, Apellis Pharmaceuticals, Rachel Eclov, Director and Development Project Leader, Kriya Therapeutics, Rama Sivasubramanian, Director - Clinical Development and Cardio-renal Development Unit, Novartis AG, Rick Artis, Senior Vice President - Chemistry, Annexon Biosciences, Sha-Mei Liao, Associate Director, Novartis AG, Sharon Barr, Senior Vice President and Head of Rare Disease Research and Product Development, Alexion Pharmaceuticals, Susan Kalled, Chief Scientific Officer, Dianthus Therapeutics, Ted Yednock, Executive Vice President and Chief Innovation Officer, Annexon Biosciences, Vaishnavi Rajagopal, Lab head, Complement Research, Sanofi, Xaria Li, Research Officer Woodruff Group of Neuroinflammation, University of Queensland, Yamini Bynagari, Vice President - Clinical Research, Machaon Diagnostics